Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: A randomized controlled study

BMC Complementary and Alternative Medicine

Volumn 11, Issue , 2011, Pages

  Debbi, Eytan M ^a   Agar, Gabriel ^a   Fichman, Gil ^a   Ziv, Yaron B ^a   Kardosh, Rami ^a   Halperin, Nahum ^a   Elbaz, Avi ^a   Beer, Yiftah ^a   Debi, Ronen ^a  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; DIMETHYL SULFONE; PLACEBO; ANTIINFLAMMATORY AGENT; DIMETHYL SULFOXIDE; SULFONE;

ADULT; AGED; AGGREGATED LOCOMOTOR FUNCTION; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FUNCTIONAL ASSESSMENT; HEALTH SURVEY; HUMAN; JOINT MOBILITY; JOINT STIFFNESS; KNEE OSTEOARTHRITIS; KNEE PAIN; KNEE SOCIETY CLINICAL RATING SYSTEM FOR KNEE SCORE; MALE; PAIN ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SHORT FORM 36; SUPPLEMENTATION; TREATMENT OUTCOME; VISUAL ANALOG SCALE; WOMAC OSTEOARTHRITIS INDEX; ANALYSIS OF VARIANCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DAILY LIFE ACTIVITY; DIET SUPPLEMENTATION; DRUG EFFECT; KNEE; LOCOMOTION; MIDDLE AGED; PAIN; QUALITY OF LIFE; WALKING DIFFICULTY;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS; DIETARY SUPPLEMENTS; DIMETHYL SULFOXIDE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KNEE JOINT; LOCOMOTION; MALE; MIDDLE AGED; MOBILITY LIMITATION; OSTEOARTHRITIS, KNEE; PAIN; PAIN MEASUREMENT; PROSPECTIVE STUDIES; QUALITY OF LIFE; SULFONES;

EID: 79959569553     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-11-50     Document Type: Article

References (36)

1. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, Jordan JM, Katz JN, Kremers HM, Wolfe F, . National Arthritis Data Workgroup Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008, 58:26-35. 10.1002/art.23176, 18163497, National Arthritis Data Workgroup.
2. Dillon CF, Rasch EK, Gu Q, Hirsch R. Prevalence of knee osteoarthritis in the United States: arthritis data from the Third National Health and Nutrition Examination Survey 1991-1994. J Rheumatol 2006, 33:2271-2279.
3. Felson DT, Lawrence RC, Hochberg MC, McAlindon T, Dieppe PA, Minor MA, Blair SN, Berman BM, Fries JF, Weinberger M, Lorig KR, Jacobs JJ, Goldberg V. Osteoarthritis: new insights. Part 2. Treatment approaches. Annals of Internal Medicine 2000, 133:726-737.
4. Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA 2002, 287:64-71. 10.1001/jama.287.1.64, 11754710.
5. Gottesdiener K, Schnitzer T, Fisher C, Bockow B, Markenson J, Ko A, DeTora L, Curtis S, Geissler L, Gertz BJ, . Protocol 007 Study Group Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology (Oxford) 2002, 41:1052-1061. Protocol 007 Study Group.
6. Dieppe P, Basler HD, Chard J, Croft P, Dixon J, Hurley M, Lohmander S, Raspe H. Knee replacement surgery for osteoarthritis: effectiveness, practice variations, indications and possible determinants of utilization. Rheumatology (Oxford) 1999, 38:73-83.
7. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000, 283:1469-1475. 10.1001/jama.283.11.1469, 10732937.
8. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002, 162:2113-2123. 10.1001/archinte.162.18.2113, 12374520.
9. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Glacovelli G, Henrotin Y, Dacre JE, Gossett C. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001, 357:251-256. 10.1016/S0140-6736(00)03610-2, 11214126.
10. Hucker HB, Miller JK, Hochberg A, Brobyn RD, Riordan FH, Calesnick B. Studies on the absorption, excretion and metabolism of dimethylsulfoxide (DMSO) in man. J Pharmacol Exp Ther 1967, 155:309-317.
11. Engelke UF, Tangerman A, Willemsen MA, Moskau D, Loss S, Mudd SH, Wevers RA. Dimethyl sulfone in human cerebrospinal fluid and blood plasma confirmed by one-dimensional (1)H and two-dimensional (1)H-(13)C NMR. NMR Biomed 2005, 18:331-336. 10.1002/nbm.966, 15996001.
12. Ebisuzaki K. Aspirin and methylsulfonylmethane (MSM): a search for common mechanisms, with implications for cancer prevention. Anticancer Res 2003, 23:453-458.
13. Alam SS, Layman DL. Dimethyl sulfoxide inhibition of prostacyclin production in cultured aortic endothelial cells. Ann N Y Acad Sci 1983, 411:318-320. 10.1111/j.1749-6632.1983.tb47314.x, 6410965.
14. Beilke MA, Collins-Lech C, Sohnle PG. Effects of dimethyl sulfoxide on the oxidative function of human neutrophils. J Lab Clin Med 1987, 110:91-96.
15. Usha P, Naidu M. Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis. Clin Drug Invest 2004, 24:353-263.
16. Kim LS, Axelrod LJ, Howard P, Buratovich N, Waters RF. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. Osteoarthritis Cartilage 2006, 14:286-294. 10.1016/j.joca.2005.10.003, 16309928.
17. Brien S, Prescott P, Lewith G. Meta-analysis of related nutritional supplements dimethyl sulfoxide and methylsulfonylmethane in the treatment of osteoarthritis of the knee. Evid Based Complement Alternat
18. Brien S, Prescott P, Bashir N, Lewith H, Lewith G. Systemic review of nutritional supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) in the treatment of osteoarthritis. Osteoarthritis Cartilage 2008, 16:1277-1288. 10.1016/j.joca.2008.03.002, 18417375.
19. Jacob SW, Appleton J. MSM: The Definitive Guide 2003, Topanga: Freedom Press.
20. Altman R, Asch E, Bloch D, Bole G, Bronstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, Howell D, Kaplan D, Koopman W, Longley S, Mankin H, McShane DJ, Medsger T, Meenan R, Mikkelsen W, Moskowitz R, Murphy W, Rothchild B, Segal M, Sokoloff L, Wolfe F. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986, 29:1039-1049. 10.1002/art.1780290816, 3741515.
21. Kellgren JH, Lawrence JS. Atlas of Standard Radiographs 1963, Oxford: Blackwell.
22. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988, 15:1833-1840.
23. Davies GM, Watson DJ, Bellamy N. Comparison of the responsiveness and relative effect size of the Western Ontario and McMaster Universities Osteoarthritis Index and the short-form Medical Outcomes Study Survey in a randomized, clinical trial of osteoarthritis patients. Arthritis Care Res 1999, 12:172-179. 10.1002/1529-0131(199906)12:3<172::AID-ART4>3.0.CO;2-Y, 10513507.
24. McCarthy CJ, Oldham JA. The reliability, validity and responsiveness of an aggregated locomotor function (ALF) score in patients with osteoarthritis of the knee. Rheumatology (Oxford) 2004, 43:514-517.
25. Kosinski M, Keller SD, Ware JE, Hatoum HT, Kong SX. The SF-36 health survey as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis: relative validity of scales in relation to clinical measures of arthritis severity. Medical Care 1999, 37(Suppl 5):MS23-39.
26. Flaherty SA. Pain measurement tools for clinical practice and research. J Am Assoc Nurse Anesth 1996, 64:133-139.
27. Wigler I, Neumann L, Yaron M. Validation study of a Hebrew version of WOMAC in patients with osteoarthritis of the knee. Clin Rheum 1999, 18:402-405.
28. Flandry F, Hunt JP, Terry GC, Hughston JC. Analysis of subjective knee complaints using visual analog scales. Am J Sports Med 1991, 19:112-118. 10.1177/036354659101900204, 2039061.
29. Insall JN, Dorr LD, Scott RD, Scott WN. Rationale of the knee society clinical rating system. Clin Orthop Relat Res 1989, 248:13-14.
30. Lingard EA, Katz JN, Wright RJ, Wright EA, Sledge CB. Validity and responsiveness of the knee society clinical rating system in comparison with the SF-36 and WOMAC. JBJS 2001, 83:1856-1864.
31. Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA 2002, 287:64-71. 10.1001/jama.287.1.64, 11754710.
32. Bjordal JM, Ljunggren AE, Klovning A, Slordal L. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ 2004, 329:1317. 10.1136/bmj.38273.626655.63, 534841, 15561731.
33. Lin J, Zhang W, Jones A, Doherty M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ 2004, 329:324. 10.1136/bmj.38159.639028.7C, 506853, 15286056.
34. Arrich J, Piribauer F, Mad P, Schmid D, Klaushofer K, Mullner M. Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis. CMAJ 2005, 172:1039-1043. 10.1503/cmaj.1041203, 556045, 15824412.
35. Day R, Morrison B, Luza A, Castaneda O, Strusberg A, Nahir M, Helgetveit KB, Kress B, Daniels B, Bolognese J, Krupa D, Seldenberg B, Ehrich E. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. Arch Intern Med 2000, 160:1781-1787. 10.1001/archinte.160.12.1781, 10871971.
36. Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000, 160:2998-3003. 10.1001/archinte.160.19.2998, 11041909.